Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tamoxifen-induced hot flashes.

C L Loprinzi1, K M Zahasky, J A Sloan

  • 1Mayo Clinic, Mayo Foundation, Rochester, MN, USA. cloprinzi@mayo.edu

Clinical Breast Cancer
|March 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Counter-Irritants.

The Journal of comparative medicine and veterinary archives·2022
Same author

Department of Surgery.

The Journal of comparative medicine and veterinary archives·2022
Same author

Department of Surgery.

The Journal of comparative medicine and veterinary archives·2022
Same author

Department of Surgery.

The Journal of comparative medicine and veterinary archives·2022
Same author

Department of Surgery.

The Journal of comparative medicine and veterinary archives·2022
Same author

Department of Surgery.

The Journal of comparative medicine and veterinary archives·2022

Tamoxifen, a common breast cancer drug, causes hot flashes in about half of users. Prior menopause symptoms and estrogen use predict who experiences severe hot flashes requiring therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Women's Health

Background:

  • Hot flashes are a significant side effect of tamoxifen, a widely used breast cancer treatment.
  • Limited data exists on predicting tamoxifen-induced hot flashes, their progression, and need for intervention.

Purpose of the Study:

  • To identify predictors of hot flash development and severity in women taking tamoxifen.
  • To describe the natural history of tamoxifen-induced hot flashes.
  • To determine the likelihood of women requesting therapy for hot flashes.

Main Methods:

  • Prospective trial involving women initiating adjuvant tamoxifen for breast cancer.
  • Baseline questionnaire assessed potential prognostic factors for hot flashes.
  • Hot flash diaries were completed daily for 3 months, then weekly for 9 months.

Related Experiment Videos

Main Results:

  • Approximately 50% of women reported substantial hot flashes.
  • Hot flashes generally increased over 3 months before plateauing.
  • Prior moderate-to-severe menopausal hot flashes and prior estrogen therapy predicted increased hot flash problems.

Conclusions:

  • Baseline factors like menopausal hot flash history and estrogen use can help predict which women will experience significant tamoxifen-induced hot flashes.
  • This information can aid in patient education and management of tamoxifen side effects.
  • About 16% of women ultimately desired therapy for their hot flashes.